AU2004324868B2 - High-dosage extended-release formulation of gepirone - Google Patents

High-dosage extended-release formulation of gepirone Download PDF

Info

Publication number
AU2004324868B2
AU2004324868B2 AU2004324868A AU2004324868A AU2004324868B2 AU 2004324868 B2 AU2004324868 B2 AU 2004324868B2 AU 2004324868 A AU2004324868 A AU 2004324868A AU 2004324868 A AU2004324868 A AU 2004324868A AU 2004324868 B2 AU2004324868 B2 AU 2004324868B2
Authority
AU
Australia
Prior art keywords
gepirone
composition
tablet
pharmaceutically acceptable
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004324868A
Other languages
English (en)
Other versions
AU2004324868A1 (en
Inventor
Stephen J Kramer
Louis F Fabre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FABRE KRAMER HOLDINGS Inc
Original Assignee
FABRE KRAMER HOLDINGS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FABRE KRAMER HOLDINGS Inc filed Critical FABRE KRAMER HOLDINGS Inc
Publication of AU2004324868A1 publication Critical patent/AU2004324868A1/en
Application granted granted Critical
Publication of AU2004324868B2 publication Critical patent/AU2004324868B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004324868A 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone Expired - Fee Related AU2004324868B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (2)

Publication Number Publication Date
AU2004324868A1 AU2004324868A1 (en) 2006-05-18
AU2004324868B2 true AU2004324868B2 (en) 2010-04-29

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004324868A Expired - Fee Related AU2004324868B2 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Country Status (11)

Country Link
EP (1) EP1809255A4 (zh)
JP (1) JP2008519071A (zh)
CN (1) CN101076320A (zh)
AU (1) AU2004324868B2 (zh)
BR (1) BRPI0419179A (zh)
CA (1) CA2585606A1 (zh)
EA (1) EA013213B1 (zh)
IL (1) IL182792A0 (zh)
MX (1) MX2007005368A (zh)
NO (1) NO20072851L (zh)
WO (1) WO2006052227A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (it) * 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
RU2713725C1 (ru) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Биологически активная добавка и способ ее применения

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
JP2004517083A (ja) * 2000-12-08 2004-06-10 アクゾ・ノベル・エヌ・ベー ジェピロンの経口用持続放出性製剤
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
MX2007005368A (es) 2007-09-11
WO2006052227A1 (en) 2006-05-18
BRPI0419179A (pt) 2007-12-18
IL182792A0 (en) 2007-08-19
AU2004324868A1 (en) 2006-05-18
EP1809255A4 (en) 2011-08-03
EA200701010A1 (ru) 2007-10-26
EP1809255A1 (en) 2007-07-25
EA013213B1 (ru) 2010-04-30
CA2585606A1 (en) 2006-05-18
NO20072851L (no) 2007-07-31
JP2008519071A (ja) 2008-06-05
CN101076320A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
US7226614B2 (en) Tablet comprising cetirizine and pseudoephedrine
AU2002345024B2 (en) Tablet comprising cetirizine and pseudoephedrine
US10500172B2 (en) Composition and method for treating neurological disease
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
US20200129454A1 (en) Composition and method for treating neurological disease
US11833121B2 (en) Composition and method for treating neurological disease
WO2009027786A2 (en) Matrix dosage forms of varenicline
AU2004324868B2 (en) High-dosage extended-release formulation of gepirone
AU2002212290B2 (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
US20060099267A1 (en) High-dosage extended-release formulation of gepirone
NZ554916A (en) High-dosage extended-release formulation of gepirone
US20050171119A1 (en) Pharmaceutical formulations with modified release
EP1569651B1 (en) Tablet comprising efletirizine and pseudoephedrine
EP3501502A1 (en) Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
KR20070093972A (ko) 게피론의 고용량 서방성 제제
CN118201603A (zh) 多颗粒药物组合物
WO2008038106A1 (en) Venlafaxine extended release formulations
US20130150375A1 (en) GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 24, NO 17, PAGE(S) 1945 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX DELETE ALL REFERENCE TO 2004324868.

TH Corrigenda

Free format text: IN VOL 24, NO 32, PAGE(S) 3739 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX DELETE ALL REFERENCE TO 2004324868.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application